Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leuprolide acetate + isopropyl alcohol is a pharmaceutical kit marketed by Sandoz, consisting of a multi-dose vial of leuprolide acetate for injection and 70% isopropyl alcohol medicated pads for site preparation. Leuprolide acetate is a synthetic nonapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH). It functions as a potent GnRH receptor agonist; while initial administration causes a transient increase in circulating levels of luteutizing hormone (LH) and follicle-stimulating hormone (FSH), continuous administration leads to the downregulation of GnRH receptors. This results in the suppression of gonadotropin secretion and a subsequent reduction in ovarian and testicular steroidogenesis to castrate or postmenopausal levels. The isopropyl alcohol component serves as a topical antiseptic to minimize the risk of infection at the subcutaneous injection site. This specific formulation is primarily utilized for the palliative treatment of advanced prostate cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leuprolide acetate + isopropyl alcohol.